(±)-NBI 74330

Cat. No. 4528 1 次引用提交评论说明书 / 分析证书（CoA） / 化学品安全技术说明书（SDS）

Pricing	Availability		Qty

说明： Potent and selective CXCR3 antagonist

化学名： N-1-[(3-4(-Ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-N-(3-pyridinylmethyl)-3-(trifluoromethyl)benzeneacetamide

纯度： ≥98% (HPLC)

引用文献 (1)

文献 (1)

生物活性技术数据溶解性计算器说明书参考文献

生物活性 for (±)-NBI 74330

(±)-NBI 74330 is a potent and selective CXCR3 antagonist; potently inhibits ¹²⁵I-CXCL10 binding to CXCR3 (pK_i = 8.13). Inhibits calcium mobilization in response to CXCL11 and CXCL10 in RBL cells. Exhibits no significant effect on chemotaxis induced by CXCR4 or CCR7. Displays a five-fold greater affinity for CXCR3 than (±)-AMG 487.

This product is racemic.

化合物库 for (±)-NBI 74330

(±)-NBI 74330 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Antiviral Library. 了解 Tocris 化合物库的更多信息。

技术数据 for (±)-NBI 74330

分子量	605.58
公式	C₃₂H₂₇F₄N₅O₃
储存	Store at -20°C
纯度	≥98% (HPLC)
CAS Number	473722-68-8
PubChem ID	10167713
InChI Key	XMRGQUDUVGRCBS-UHFFFAOYSA-N
Smiles	CCOC(C=C3)=CC=C3N2C(C1=CC=CN=C1N=C2C(N(CC4=CC=CN=C4)C(CC5=CC(C(F)(F)F)=C(F)C=C5)=O)C)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for (±)-NBI 74330

	溶剂	最高浓度 mg/mL	最高浓度 mM
溶解性
溶解性	DMSO	30.28	50

制备储备液 for (±)-NBI 74330

以下数据基于产品分子量 605.58。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

浓度/溶剂体积/质量	1 mg	5 mg	10 mg
0.5 mM	3.3 mL	16.51 mL	33.03 mL
2.5 mM	0.66 mL	3.3 mL	6.61 mL
5 mM	0.33 mL	1.65 mL	3.3 mL
25 mM	0.07 mL	0.33 mL	0.66 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

产品说明书 for (±)-NBI 74330

分析证书/产品说明书

化学品安全技术说明书

参考文献 for (±)-NBI 74330

参考文献是支持产品生物活性的出版物。

Storelli et al (2007) Synthesis and structure-activity relationships of 3H-quinazolin-4-ones and 3H-pyrido[2,3-d]pyrimidin-4-ones as CXCR3 receptor antagonists. Arch.Pharm. 340 281 PMID: 17562560

Verzijl et al (2008) Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors. J.Pharmacol.Exp.Ther. 325 544 PMID: 18270317

Heise et al (2005) Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J.Pharmacol.Exp.Ther. 313 1263 PMID: 15761110

If you know of a relevant reference for (±)-NBI 74330, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Chemokine CXC Receptor Antagonists

关键词: (±)-NBI 74330, (±)-NBI 74330 supplier, VUF10472, (±)-NBI74330, potent, selective, CXCR3, antagonists, chemokines, (±)-NBI_74330, Chemokine, CXC, Receptors, 4528, Tocris Bioscience

1 篇 (±)-NBI 74330 的引用文献

引用文献是使用了 Tocris 产品的出版物。 (±)-NBI 74330 的部分引用包括：

Piotrowska et al (2018) Pharmacological blockade of CXCR3 by (±)-NBI-74330 reduces neuropathic pain and enhances opioid effectiveness - Evidence from in vivo and in vitro studies. Biochim.Biophys.Acta 1864 3418 PMID: 30076959

您是否知道使用了 Tocris (±)-NBI 74330 的优秀论文？请告知我们.

(±)-NBI 74330 的评论

目前没有该产品的评论。 Be the first to review (±)-NBI 74330 and earn rewards!

Have you used (±)-NBI 74330?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.